June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Significance of measuring immune mediators for differentiating malignant from benign pigmented intraocular tumors
Author Affiliations & Notes
  • Yoshihiko Usui
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Shunichiro Ueda
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Yoko Okunuki
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Kinya Tsubota
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Kazuki Tajima
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Takeshi Kezuka
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Yoshihiro Wakabayashi
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Hiroshi Goto
    Ophthalmology, Tokyo Medical Univ Hospital, Shinjuku-ku, Japan
  • Footnotes
    Commercial Relationships Yoshihiko Usui, None; Shunichiro Ueda, None; Yoko Okunuki, None; Kinya Tsubota, Tokyo Medical Univercity (E); Kazuki Tajima, None; Takeshi Kezuka, None; Yoshihiro Wakabayashi, None; Hiroshi Goto, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 169. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Yoshihiko Usui, Shunichiro Ueda, Yoko Okunuki, Kinya Tsubota, Kazuki Tajima, Takeshi Kezuka, Yoshihiro Wakabayashi, Hiroshi Goto; Significance of measuring immune mediators for differentiating malignant from benign pigmented intraocular tumors. Invest. Ophthalmol. Vis. Sci. 2013;54(15):169.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Currently, malignant and benign pigmented intraocular tumors are differentiated by comprehensive judgment of clinical findings based on ophthalmoscopic examination and imaging findings. However, the differentiation is often difficult. The aim of this study was to examine the usefulness of measuring immune mediators in aqueous humor samples to differentiate malignant from benign pigmented intraocular tumors.

Methods: In 29 eyes (13 with benign pigmented tumor, 16 with malignant melanoma), undiluted aqueous humor samples were collected, and cytometric bead array was used to determine the aqueous humor concentrations of 35 immune mediators including 14 interleukins (IL), interferon (IFN)-γ, interferon-γ-inducible protein (IP)-10, monocyte chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1α, MIP-1β, regulated on activation, normal T cell expressed and secreted (RANTES), monokine induced by interferon-γ (Mig), basic fibroblast growth factor (bFGF), Fas ligand, granzyme A, granzyme B, eotaxin, interferon-inducible T-cell a chemoattractant (ITAC), fractalkine, granulocyte macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), vascular endothelial growth factor (VEGF), angiogenin, tumor necrosis factor (TNF)-α, LT-α, and CD40L.

Results: Aqueous humor levels of angiogenin and MCP-1 were significantly higher in eyes with malignant melanoma than in those with benign tumor (p<0.05).

Conclusions: The results of our study demonstrate the applicability of MCP-1 and angiogenin in aqueous humors as useful marker in distinguishing malignant and benign pigmented intraocular tumors and may be helpful as an adjunct to histomorphology and other markers in the diagnosis and appropriate clinical management.

Keywords: 744 tumors • 490 cytokines/chemokines • 557 inflammation  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×